Cytochrome P450 2C9-CYP2C9VAN BOOVEN, Derek; MARSH, Sharon; MCLEOD, Howard et al.Pharmacogenetics and genomics (Print). 2010, Vol 20, Num 4, pp 277-281, issn 1744-6872, 5 p.Article

CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese populationALLABI, Aurel C; GALA, Jean-Luc; HORSMANS, Yves et al.Pharmacogenetics and genomics (Print). 2005, Vol 15, Num 11, pp 779-786, issn 1744-6872, 8 p.Article

Discovery of new potentially defective alleles of human CYP2C9BLAISDELL, Joyce; JORGE-NEBERT, Lucia F; COULTERA, Sherry et al.Pharmacogenetics (London). 2004, Vol 14, Num 8, pp 527-537, issn 0960-314X, 11 p.Article

Influence of CYP2C9 genetic variants on gastrointestinal bleeding associated with nonsteroidal anti-inflammatory drugs: a systematic critical reviewESTANY-GESTAL, Ana; SALGADO-BARREIRA, Angel; SANCHEZ-DIZ, Paula et al.Pharmacogenetics and genomics (Print). 2011, Vol 21, Num 7, pp 357-364, issn 1744-6872, 8 p.Article

Pharmacogenomics of coumarin anticoagulants : Are we underestimating the role of CYP2C9?SCHALEKAMP, Tom; MAITLAND -VAN DER ZEE, Anke-Hilse; DE BOER, Anthonius et al.Thrombosis and haemostasis. 2008, Vol 100, Num 2, pp 175-176, issn 0340-6245, 2 p.Article

Differential Genotype Dependent Inhibition of CYP2C9 in HumansKUMAR, Vikas; BRUNDAGE, Richard C; OETTING, William S et al.Drug metabolism and disposition. 2008, Vol 36, Num 7, pp 1242-1248, issn 0090-9556, 7 p.Article

Re-engineering of CYP2C9 to Probe Acid-Base Substrate SelectivityGUOYING TAI; DICKMANN, Leslie J; MATOVIC, Nicholas et al.Drug metabolism and disposition. 2008, Vol 36, Num 10, pp 1992-1997, issn 0090-9556, 6 p.Article

Principal Component Analysis of CYP2C9 and CYP3A4 Probe Substrate/Inhibitor PanelsNATH, Abhinav; ATKINS, William.Drug metabolism and disposition. 2008, Vol 36, Num 11, pp 2151-2155, issn 0090-9556, 5 p.Article

Frequency of cytochrome P450 2C9 mutant alleles in a Korean populationYOON, Young-Ran; SHON, Ji-Hong; KIM, Moon-Kyung et al.British journal of clinical pharmacology. 2001, Vol 51, Num 3, pp 277-280, issn 0306-5251Article

Pharmacogenetics of oral anticoagulantsDALY, Ann K; KING, Barry P.Pharmacogenetics (London). 2003, Vol 13, Num 5, pp 247-252, issn 0960-314X, 6 p.Article

Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteersKIRCHHEINERA, Julia; MEINEKE, Ingolf; MÜLLER, Gunnar et al.Pharmacogenetics (London). 2002, Vol 12, Num 7, pp 571-580, issn 0960-314X, 10 p.Article

Molecular functionality of CYP2C9 polymorphisms and their influence on drug therapyYAZUN BASHIR JARRAR; LEE, Su-Jun.Drug metabolism and drug interactions. 2014, Vol 29, Num 4, pp 211-220, issn 0792-5077, 10 p.Article

Simultaneous Determination of Warfarin and 7-Hydroxywarfarin Enantiomers by High-Performance Liquid Chromatography With Ultraviolet DetectionMIURA, Masatomo; OKUYAMA, Shin; KATO, Shoutaro et al.Therapeutic drug monitoring. 2011, Vol 33, Num 1, pp 108-114, issn 0163-4356, 7 p.Article

Pharmacokinetics and safety of the sesame lignans, sesamin and episesamin, in healthy subjectsTOMIMORI, Namino; TANAKA, Yasuhiro; KITAGAWA, Yoshinori et al.Biopharmaceutics & drug disposition. 2013, Vol 34, Num 8, pp 462-473, issn 0142-2782, 12 p.Article

CYP2C9 polymorphisms in human tumorsKNÜPFER, Heike; STANITZ, Dirk; PREISS, Rainer et al.Anticancer research. 2006, Vol 26, Num 1A, pp 299-305, issn 0250-7005, 7 p.Article

Mild hypoglycaemic attacks induced by sulphonylureas related to CYP2C9, CYP2C19 and CYP2C8 polymorphisms in routine clinical settingGÖKALP, Osman; GUNES, Arzu; CAM, Hakan et al.European journal of clinical pharmacology. 2011, Vol 67, Num 12, pp 1223-1229, issn 0031-6970, 7 p.Article

R(+)XK469 inhibits hydroxylation of S-warfarin by CYP2C9WEI PENG YONG; TAE WON KIM; UNDEVIA, Samir D et al.European journal of cancer (1990). 2009, Vol 45, Num 11, pp 1904-1908, issn 0959-8049, 5 p.Article

Enzyme source effects on CYP2C9 kinetics and inhibitionKUMAR, Vikas; ROCK, Dan A; WARREN, Chad J et al.Drug metabolism and disposition. 2006, Vol 34, Num 11, pp 1903-1908, issn 0090-9556, 6 p.Article

Malaysian Indians are genetically similar to Caucasians : CYP2C9 polymorphismZAINUDDIN, Z; TEH, L. K; SUHAIMI, A. W. M et al.Journal of clinical pharmacy and therapeutics (Print). 2006, Vol 31, Num 2, pp 187-191, issn 0269-4727, 5 p.Article

Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide eliminationELLIOT, David J; SUHARJONO; LEWIS, Benjamin C et al.British journal of clinical pharmacology. 2007, Vol 64, Num 4, pp 450-457, issn 0306-5251, 8 p.Article

Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek populationARVANITIDIS, Kostas; RAGIA, Georgia; IORDANIDOU, Maria et al.Fundamental & clinical pharmacology. 2007, Vol 21, Num 4, pp 419-426, issn 0767-3981, 8 p.Conference Paper

Obesity is associated with a slower response to initial phenprocoumon therapy whereas CYP2C9 genotypes are notZU SCHWABEDISSEN, Cordula Meyer; MEVISSEN, Vera; SCHMITZ, Fabian et al.European journal of clinical pharmacology. 2006, Vol 62, Num 9, pp 713-720, issn 0031-6970, 8 p.Article

CYP2C9 inhibition : Impact of probe selection and pharmacogenetics on in vitro inhibition profilesKUMAR, Vikas; WAHLSTROM, Jan L; ROCK, Dan A et al.Drug metabolism and disposition. 2006, Vol 34, Num 12, pp 1966-1975, issn 0090-9556, 10 p.Article

The pharmacogenetics of the response to warfarin in ChineseLAM, May P. S; CHEUNG, Bernard M. Y.British journal of clinical pharmacology. 2012, Vol 73, Num 3, pp 340-347, issn 0306-5251, 8 p.Article

Eltrombopag, an oral thrombopoietin receptor agonist, has no impact on the pharmacokinetic profile of probe drugs for cytochrome P450 isoenzymes CYP3A4, CYP1A2, CYP2C9 and CYP2C19 in healthy men: a cocktail analysisJENKINS, Julian; WILLIAMS, Daphne; YANLI DENG et al.European journal of clinical pharmacology. 2010, Vol 66, Num 1, pp 67-76, issn 0031-6970, 10 p.Article